Dimethyl Sulfoxide USP, PhEur in Approved Pharmaceutical Products and Medical Devices - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Dimethyl Sulfoxide USP, PhEur in Approved Pharmaceutical Products and Medical Devices
The authors survey the approved applications of dimethyl sulfoxide USP, PhEur across the healthcare industry and consider the suitability of DMSO from a regulatory and formulation compatibility standpoint.


Pharmaceutical Technology



Figure 1: DMSO gel viscosity as a function of polymer loading. (MARTIN POOLE/GETTY IMAGES)
For highly viscous gel products, loading levels of 1.5–2.0 wt% are required, and it may be helpful to warm the product (~50 C) during the mixing process. Carbomer-type thickening agents (e.g., Carbopol) are especially recommended for use with DMSO for their high clarity and gel stability. Figure 1 provides viscosity data at varying loading levels for Carbopol 941.


Table IV: Miscellaneous excipient solubilities in dimethyl sulfoxide.*
Carbohydrates and miscellaneous excipients. Some carbohydrates are freely soluble in DMSO (e.g., β- and D-lactose, sucrose). Table IV provides solubility data for various polymeric excipient products, carbohydrates, and some miscellaneous materials.

Consideration of packaging components. DMSO interacts physically with many polymeric materials (swelling, dissolution). As such, high-density polyethylene, high-density polypropylene, and polytetrafluoroethylene are the only materials suitable for packaging a product containing high levels of DMSO. Product formulations using DMSO with other cosolvents or ingredients should perform package testing to confirm compatibility.

Product odor. Dimethyl sulfoxide, USP, PhEur is a highly pure pharmaceutical product and does not have the odor that has been associated with some industrial materials. When purified, DMSO is essentially odorless.

Regulatory affairs

Compendial status and manufacturing aspects. Three monographs exist in the 2005 USP–NF that reference DMSO (19). These are dimethyl sulfoxide gel, dimethyl sulfoxide irrigation, and dimethyl sulfoxide topical solution. A monograph is established in the European Pharmacopoeia under dimethyl sulfoxide (20).

Dimethyl sulfoxide USP, PhEur is manufactured in the US under Q7 good manufacturing guidelines established by the International Conference on Harmonization (ICH) for APIs. These guidelines have been adopted by FDA. The chemistry, manufacturing, and controls (CMC) of DMSO are described in a type II drug master file on file with FDA and Health Canada. Applicants may reference the drug master file through its holder, Gaylord Chemical Co. LLC. Dimethyl sulfoxide USP, PhEur is certified kosher parve.

Dimethyl sulfoxide USP, PhEur does not hold generally regarded as safe (GRAS) status as defined in sections 201(s) and 409 of the US Federal Food, Drug, and Cosmetic Act. As such, the product is not intended for food use and is subject to premarket review in food applications. DMSO has no existing food applications.

As provided in its "Q3C Impurities: Residual Solvents" guidelines, ICH further designates DMSO a Class 3 residual solvent when used in the manufacture of pharmaceutical products. Class 3 solvents are those considered to represent a low toxic potential (21).

Historical aspects. Any discussion of DMSO in pharmaceutical applications would be incomplete without mentioning the "wonder drug" status defined for DMSO in the public and lay press in the 1960s and 1970s (22). As important, the public's fascination with—and in some cases, abuse of—DMSO has undoubtedly influenced the approval process for formulated drug products that contain it.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
29%
Oversee medical treatment of patients in the US.
11%
Provide treatment for patients globally.
7%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
Source: Pharmaceutical Technology,
Click here